CLDX•benzinga•
Celldex Therapeutics Presents Preclinical Data From Inflammatory Bispecific Antibody Program CDX-622 At AAAAI 2025; CDX-622 Inhibits SCF And TSLP-Dependent Inflammatory Signatures In Human Skin
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga